GI Complaints cured with s. boulardii and colostrum

[Guest guest]

These three papers from Dr Stuppy of Los Angeles, a Harvard

trained gastroenterologist and pathologist, should be very alarming

to you. They show that nasty parasites are extremely common in

anyone with GI complaints. These include Amoeba, Cryptosporidium, C

Difficile, Giardia, Blastocystis, and Helicobacter with often more

than one present making eradication complex.

ACG 2006: The American College of Gastroenterology Annual Scientific

Meeting

Abstract Number: 1000

Contact Person: P. Stuppy, MD

Department/Institution: Private Practice

Address: 637 Lucas Ave., #212

City/State/Zip/Country: Los Angeles, CA, 90017, United States

Phone: (323) 464-4242 Fax: E-mail: w.stuppy@...

Awards: No award selected

Abstract Categories: 7. Clinical Vignettes / 10. Functional Bowel

Disorders

Presentation Preference: Either Oral or Poster Only

ACG Research Grant: No

Keywords: gastrointestinal infection, parasitosis, dysbiosis.

Title: Chronic Gastrointestinal Infections/Parasitosis in Clinical

Practice

P. Stuppy, MD. 1Private Practice, Los Angeles, California,

United States.

Purpose: Patients seen in consultation for non-specific

gastrointestinal complaints (foregut, midgut, and hindgut)

with 'negative' endoscopies, stool for O & P, and abdominal ultrasound

are often dismissed as 'functional' disorders. The purpose of this

report is disclose the presence of chronic gastrointestinal

infection/parasitosis in such a population over ten years of

practice.

Methods: Patients (672) referred for non-specific gastrointestinal

dysfunction were tested for the presence of infection/parasitosis. A

combination of saliva (IgA and IgG), stool (microscopic and antigen

detection by florescence microscopy) by Diagnos-Techs, Inc. are the

subjects of this report.

Results:

NUMBER OF PATIENTS= 672

Cryptosporidium parvum 243

Amoeba histolytica 213

Helicobacter pylori 212

Giardia lambium 163

C. difficile 114

Blastocystis hominis 41

Ascaris lumbricoides 64

Tinea solium 32

Trichinella spiralis 23

NUMBER OF INFECTIONS/PARASITES= 2210

Conclusion: Patients with chronic gastrointestinal complaints

without demonstrable pathology by endoscopic or radiographic

examination are likely to have infections/parasitosis. A third of

these have more than one pathogen. A third of patients are

spouses, 'significant others', children. This indicates person to

person transmission is the primary path for these disorders and

these conditions are grossly underestimated.

Disclosure:

I.

My presentation will include discussion of commercial products or

services.

I do not have a relevant financial relationship with the manufacturer

(s)

II.

Who initiated the research? Investigator

Reason for the research: was it for FDA approval or FDA treatment

indication? No

Who designed the study? Investigator

Who performed the analyses? Investigator

Did the investigator contribute patients to the study? Yes

Who wrote the manuscript? Investigator

Are these the main results of the study? Yes

If no, are these the results of secondary analyses? No response.

ACG 2006: The American College of Gastroenterology Annual Scientific

Meeting

Abstract Number: 1360

Contact Person: P. Stuppy, MD

Department/Institution: Private Practice

Address: 637 Lucas Ave., #212

City/State/Zip/Country: Los Angeles, CA, 90017, United States

Phone: 323 464-4242 Fax: E-mail: w.stuppy@...

Awards: No award selected

Abstract Categories: 7. Clinical Vignettes / 8. Outcomes Research

Presentation Preference: Either Oral or Poster Only

ACG Research Grant: No

Keywords: gastrointestinal infection, parasitosis, Nitazoxanide.

Title: Nitazoxanide And Treatment of Gastrointestinal

Infections/Parasitosis.

P. Stuppy, MD. 1Private Practice, Los Angeles, CA, United

States.

Purpose: Hundreds of patients (672) with thousands (2210) of

gastrointestinal infections/parasites have been treated over the

past ten years. A third of these have more than one parasite making

treatment a challenge. Two hundred and fifty four (254) were treated

with one drug, Nitazoxanide 1 GM., PO, BID. The purpose of this

report is to suggest that 'one drug' therapy will eradicate chronic

gastrointestinal infection (bacteria, amoeba, helminth) in most

patients.

Methods: Of 672 patients 2210 were found to have gastrointestinal

infection/parasitosis. A third had more than one parasite. Those

with more than one (254) were prescribed one drug, Nitazoxanide (1

gram, PO, BID, for two weeks).

Results:

Patients Treated With Nitazoxanide (254)

ORGANISM/PATHOGEN CASES ERADICATION SUCCESS

Cryptosporidium parvum 243 240 99%

Amoeba histolyticum 112 112 100%

Giadria lambia 120 118 98%

Blastocystis hominis 23 22 96%

Ascaris lumbricides 30 27 90%

C. difficile 27 27 100%

T. solium 22 22 100%

T. spiralis 11 11 100%

Conclusion: Nitazoxanide is highly effective in treating/eradicating

gastrointestinal pathogens; this includes parasites, helminths,

protozoa, and pathologic bacteria.

Disclosure:

I.

My presentation will include discussion of commercial products or

services.

I do not have a relevant financial relationship with the manufacturer

(s)

II.

Who initiated the research? Investigator

Reason for the research: was it for FDA approval or FDA treatment

indication? No

Who designed the study? Investigator

Who performed the analyses? Investigator

Did the investigator contribute patients to the study? Yes

Who wrote the manuscript? Investigator

Are these the main results of the study? Yes

If no, are these the results of secondary analyses? No response.

ACG 2006: The American College of Gastroenterology Annual Scientific

Meeting

Abstract Number: 1361

Contact Person: P. Stuppy, MD

Department/Institution: Private Practice

Address: 637 Lucas Ave., #212

City/State/Zip/Country: Los Angeles, CA, 90017, United States

Phone: 323 464-4242 Fax: E-mail: w.stuppy@...

Awards: No award selected

Abstract Categories: 7. Clinical Vignettes / 6. Colon

Presentation Preference: Either Oral or Poster Only

ACG Research Grant: No

Keywords: Clostridium difficile, Saccharomyces boulardii, colostrum.

Title: Probiotics and Colostrum in the Treament of C. difficile

Colitis

P. Stuppy, MD. 1Private Practice, Los Angeles, CA.

Purpose: Clostridium difficile colitis (Toxins A & is a major

pathogen in both in- and out-patient settings. Allopathic therapy is

equally dangerous. The purpose of this study is to share the

experience of treatment of C. difficile with probiotics and

colostrum.

Methods: One hundred and fourteen patients with C. difficile were

seen. Eighty seven were treated with a 'probiotic', Saccharomyces

boulardii (250 mgm) and colostrum (960 mgm), PO, BID for two weeks.

Results: Eighty five of eighty seven patients were found free of C.

difficile toxins A & B after two weeks of the probiotic S. boulardii

and colostrum.

Conclusion: Treatment of C. difficile toxins should begin with

probiotics and colostrum, not antibiotics. Most cases of C.

difficile are caused by antibiotics. Fight fire with fire.

Disclosure:

I.

My presentation will not include discussion of commercial products

or services

II.

Who initiated the research? Investigator

Reason for the research: was it for FDA approval or FDA treatment

indication? No

Who designed the study? Investigator

Who performed the analyses? Investigator

Did the investigator contribute patients to the study? Yes

Who wrote the manuscript? Investigator

Are these the main results of the study? Yes

If no, are these the results of secondary analyses? No